Open Label Clinical Trial of Anascorp® in Pediatric Patients With Scorpion Sting Envenomation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01599936|
Recruitment Status : Completed
First Posted : May 16, 2012
Last Update Posted : March 22, 2016
|Condition or disease||Intervention/treatment||Phase|
|Scorpion Sting||Biological: Anascorp||Phase 3|
The purpose of this open label, confirmatory, controlled clinical trial was to examine the safety and efficacy of Alacramyn® for treatment of patients envenomed by scorpion sting.
This study took place at San Carlos Indian Hospital in San Carlos, Arizona and in two pediatric Intensive care units in Tucson, Arizona.
Patients who arrived at the emergency department presenting with scorpion sting symptoms were evaluated for treatment with respect to the inclusion/exclusion criteria according to the study procedures. Only patients with clinically important systemic signs of scorpion sting envenomation were included in the study. Baseline measures included severity evaluation of the scorpion sting envenomation. The patient's vital signs, concomitant medication, medical history and demographic data were collected. Blood tests were done for haematology, chemistry, venom and anti-venom levels and urine test.
After informed consent and inclusion/exclusion criteria were obtained and verified, and the baseline measurements completed, three vials of Alacramyn® were administered. At the one hour assessment an additional vial of Alacramyn® was administered if important systemic signs of scorpion envenomation were present. The assessment was repeated at two hours and a final vial of Alacramyn® was administered if deemed necessary. Patient were discharged after the 4 hour assessment if symptoms were resolved. Prior to discharge repeat lab work, physical assessments, and vital signs were done. Those remaining for extended care underwent final study assessments at time of hospital discharge or at 24 hours after study drug infusion if hospitalization continued.
All patients who participated in the study were contacted 7 and 14 days after treatment, looking for symptoms suggestive of ongoing venom effect, delayed serum sickness, as well as for any other adverse event reported by the patient.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Open Label, Confirmatory, Controlled Clinical Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation|
|Study Start Date :||April 2004|
|Actual Primary Completion Date :||October 2006|
|Actual Study Completion Date :||June 2007|
Three vials of Anascorp® will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access
3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
Other Name: Antivenin Centruroides (scorpion) equine immune F(ab')2
- Resolution of clinically important systemic signs of scorpion envenomation within four hours after Alacramyn administration. [ Time Frame: Assessments conducted at 1, 2 and 4 hours post administration ]
- Demonstrate that venom blood levels will decrease within one hour after Alacramyn® treatment. [ Time Frame: One hour ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01599936
|United States, Arizona|
|San Carlos Indian Hospital|
|San Carlos, Arizona, United States, 85550|
|Tucson Medical Center|
|Tucson, Arizona, United States, 85712|
|University Medical Center|
|Tucson, Arizona, United States, 85724|
|Study Director:||Walter Garcia Ubbelohde, MD||Instituto Bioclon|
|Principal Investigator:||Leslie V. Boyer, MD||VIPER Institute, University of Arizona|
|Study Chair:||Alejandro Alagon, PhD||Universidad Nacional Autonoma de Mexico|